JBIO Aerovate Total Asset Value of Company
This daily price chart of Aerovate Therapeutics Inc (JBIO) total assets on GURU.Markets, which reached 309.90, serves as confirmation of the market valuation and highlights the business's vulnerability due to potential failures in pulmonary hypertension trials. Aerovate Therapeutics Inc minimizes these threats by developing inhalation therapies for rare lung pathologies. The stability of laboratory operations is guaranteed through the use of secure global transportation routes for biochemical components.
Analytical breakdowns and data insights for company aerovatetx.com (JBIO)
- stock value and consensus price forecast:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Aerovate Therapeutics Inc|JBIO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Aerovate Therapeutics|JBIO - Company Aggregate Debts|Debts to Book Capitalization JBIO|JBIO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Aerovate Therapeutics Inc|Interim Coverage Ratio aerovatetx.com
- net income and valuation multiples indicators:
Fundamental valuation:Aerovate Therapeutics Inc
An investment audit of Aerovate Therapeutics Inc (JBIO) requires a precise assessment of the resource base before entering the asset. Total assets here are determined reversely via ROA, reflecting the aggregate of capital and liabilities within the dynamics of market equilibrium. For Aerovate Therapeutics Inc, this volume of resources supports the development of specialized inhalation systems, minimizing scientific risks. Analyzing the growth of property and resources allows for balancing the company's liquidity against innovation costs.
Key competitors
Company Assets argenx.com (ARGX)|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|Savara Corp - Company Total Assets|RIGL - Company Total Assets|ANAB: Company Total Assets|Company Assets astriatx.com (ATXS)|Aggregate Company Assets enGene|RAPT: Aggregate Asset Value|Aggregate Company Assets Aclaris (ACRS)|KYTX - Company Assets|Tiziana Life Sciences - Cumulative Company Assets|cabalettabio.com - Aggregate Company Assets|Ventyx Biosciences, Inc. - Company Total Assets|THTX - Company Total Assets|AVTX (Avalo Therapeutics Inc.) - Cumulative Company Assets|ELDN: Aggregate Business Assets|AGEN (Agenus) - Company Total Assets|Company Assets climbbio.com CLYM|Cumulative Company Assets ZURA (Zura Bio)|ATYR (aTyr Pharma Inc) - Aggregate Asset Value|Adagene Inc. - Cumulative Company Assets|Aggregate Business Assets IMA (ImageneBio)|Shattuck Therapeutics - Company Total Assets|Aggregate Asset Value EQ (Equillium, Inc.)|CNTB: Company Total Assets|Company Assets Immunic (IMUX)|Aggregate Company Assets Atara Biotherapeutics, Inc.|IFRX: Aggregate Asset Value|Company Total Assets XFOR|Company Total Assets adicetbio.com (ACET)|Aggregate Company Assets Celularity CELU|INMB (INmune Bio Inc) - Total Asset Value of Company|Barinthus Bio - Company Total Assets|Company Assets Kezar Life Sciences Inc|SABS (SAB Biotherapeutics) - Cumulative Company Assets|akaritx.com (AKTX) - Company Total Assets|Cumulative Company Assets ENLV|QTTB (Q32 Bio Corp) - Aggregate Business Assets|Company Total Assets GOVX|Company Total Asset Base Edesa Biotech Corp|Company Total Assets IBIO (iBio, Inc.)|CARM - Cumulative Company Assets|XTLB - Aggregate Company Assets|Company Total Asset Base Bolt Biotherapeutics BOLT|HCWB (hcwbiologics.com) - Cumulative Company Assets|Aptevo Therapeutics Inc. - Aggregate Asset Value|AIM (AIM ImmunoTech Inc.) - Company Total Assets|Aditxt Corp (ADTX) - Company Total Asset Base|Aggregate Company Assets GRI Bio (GRI)|XORTX Therapeutics Inc - Total Business Assets|Company Total Assets HIND (ReShape Lifesciences)|REVB - Cumulative Company Assets|INDP - Aggregate Company Assets|scinai.com - Aggregate Business Assets|CALI: Company Total Assets|AFMD (Affimed N.V.) - Aggregate Company Assets|ALLK (Allakos Inc) - Company Total Assets|HOOKIPA (HOOK) - Company Total Asset Base|Aggregate Company Assets IGM Biosciences, Inc. (IGMS)|ITOS - Company Assets|Aggregate Company Assets Ocean Biomedical OCEA|TCBP (TC BioPharm (Holdings) Plc) - Total Asset Value of Company|Third Harmonic Bio, Inc - Company Total Assets